HYMPAVZI’s approval is based on Phase 3 study results demonstrating substantial bleed reduction compared to routine prophylaxis
Aims to achieve CDMO sales of US$ 400 million by 2028
Clarity in regulatory frameworks and pathways help in preventing delays in accessing quality-assured, affordable medicines
To set a new standard in oncology, offering highly targeted radiation therapy that improves treatment precision, and accelerates recovery for cancer patients
WCK 6777 is the only once-a-day drug in global antibiotic pipeline designed for outpatient parenteral antimicrobial therapy
CSPC will receive an upfront payment of $100 million from AstraZeneca
Based on ECHO Phase III trial which demonstrated Calquence combination reduced risk of disease progression or death by 27% compared to standard-of-care chemoimmunotherapy
he company will focus on production of any pharmaceutical and biotechnological products
The company plans to advance Ropanicant into double-blind, placebo-controlled Phase-2b clinical study in MDD patients, anticipated to start in early 2025
Expansion includes a new 5-story, 136k sq. ft. multipurpose building in Sejong
Subscribe To Our Newsletter & Stay Updated
